Roache, Ph.D., John DSchool of Medicine |
|
|
John D. Roache, Ph.D. is Deputy Chair for Research and Chief of the Division of Alcohol and Drug Addiction in the Department of Psychiatry. He also serves as the Director of the FIRST Program which is the clinical research arm of the Institute on the Integration of Medicine & Science (IIMS). His research expertise is in understanding the behavioral biology of addiction and in designing and conducting clinical trials to develop new treatments for addiction. |
|
| 9/2008 - Present | Deputy Chair for Research | UT Health Science Center - San Antonio, Psychiatry |
| 6/2008 - Present | Director, FIRST Program of the CTSA-Institute for the Integration of Medicine and Science | UT Health Science Center - San Antonio, Medicine |
| 9/2007 - Present | Chief, Division of Alcohol & Drug Addiction | UT Health Science Center - San Antonio, Psychiatry |
| 9/2005 - Present | Director, Behavioral Wellness Center for Clinical Trials | UT Health Science Center - San Antonio, Psychiatry |
| 9/2002 - Present | Professor of Psychiatry with Tenure | UT Health Science Center - San Antonio, Psychiatry |
| 7/1998 - Present | Allied Health Professional Member of the Medical-Dental Staff | University Health System, University Hospital, San Antonio, TX |
| Year | Degree | Discipline | Institution |
| 1987 | Postdoctoral Fellowship | Clinical Pharmacology Research | Addiction Research Center, National Institute on Drug Abuse Baltimore , MD |
| 1985 | Postdoctoral Fellowship | Department of Psychiatry & Behavioral Sciences | The Johns Hopkins University School of Medicine Baltimore , MD |
| 1983 | PhD | Pharmacology & Toxicology | Purdue University West Lafayette , IN |
| 1980 | MS | Pharmacology & Toxicology | Purdue University West Lafayette , IN |
| 1977 | BS | Biology | Indiana University Bloomington , IN |
Basic BioBehavioral Vulnerability- Dr. Roaches research in Human Behavioral Pharmacology has helped to advance experimental methods and our understanding of the biobehavioral vulnerability to drug addiction and its treatment. |
Medications Development for Addictions Treatment- Dr. Roache has employed basic experimental psychopharmacological laboratory methods to develop novel approaches to Phase I, II and III Clinical Trials in the treatment of drug addiction. |
Research Administration- Dr. Roache serves as Deputy Chair for Research in the Dept. Psychiatry and has organized and directed research operations of the University Clinical Psychopharmacology Laboratory and also the Behavioral Wellness Center for Clinical Trials as part of the Dept. Psychiatry. He also serves as Director of the FIRST Program which is the clinical research support core of the institutional CTSA grant supporting the Institute on the Integration of Medicine & Science (IIMS). |
Journal Article |
| McCammon MG, Fogg TT, Jacobsen L, Roache JD, Sampson R, and Bower CL. Cost Recovery for Federally Funded Research - A Scientific Approach to a Translational Challenge (in press) Science Translational Medicine 2012 Jan;. |
| Somoza ED, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway G, Reid M, Segal S, Sheehan M, Roache JD, Bickely W, Jasinski D, Watson DW, Miller SR, Somoza P, and Winhusen T (in press). A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence (in press) Archives General Psychiatry 2012 Jan;. |
| Johnson, BA, Ait-Daoud, N, Seneviratne, C, Roache, JD, Javors MA, Wang XQ, Liu L, Penberthy, JK, DiClementee CC, and Li MD. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking American Journal of Psychiatry 2011 Jan;168:265-275. |
| Cigrang JA, Rauch SAM, Avila AL, Bryan CJ, Goodie JL, Hryshko-Mullen A, Peterson AL & the STRONG STAR Consortium (includes JD Roache). Treatment of active-duty military with PTSD in primary care: Early findings Psychological Services 2011 Jan;8:104-113. |
| Roache, JD, Kahn R, Newton TF, Wallace CL, Murff WL, De La Garza R, Rivera O, Anderson A, Mojsiak J, and Elkashef A. A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram Drug and Alcohol Dependence 2011 Jan;119:37-45. |
| Miller, J and Roache, JD. Benefits of topiramate treatment in a dual diagnosis patient Psychosomatics 2009 Jan;50(4):426-427. |
| Ait-Daoud, N, Roache, JD, Dawes, MA, Wang, XQ, Javors MA, Seneviratne C, and Johnson BA. Can serotonin transporter genotype predict craving in alcoholism? Clinical & Experimental Research 2009 Jan;33(8):1329-1335. |
| Dawes MA, Roache JD, Javors MA, Bergeson SE, Richard DM, Mathias CW, Ait-Daoud N, Dougherty DM, Johnson BA. Drinking histories in alcohol-use-disordered youth: preliminary findings on relationships to platelet serotonin transporter expression with genotypes of the serotonin transporter Journal of Studies on Alcohol and Drugs 2009 Jan;70:899-907. |
| Anderson, AL, Reid, MS, Li, SH, Holmes, T, Shemanski, L, Slee, A, Smith, EV, Kahn, R, Chiang, N, Vocci, F, Ciralul, D, Dackis, C, Roache, JD, Salloum, IM, Somoza, E, Urschel HC, and Elkashef, AM. Modafinil for the treatment of cocaine dependence Drug & Alcohol Dependence 2009 Jan;104:133-139. |
| Roache JD, Wang Y, Ait-Daoud N, Johnson BA. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of Alcoholism Alcoholism: Clinical and Experimental Research 2008 Jan;32:1-11. |
| Johnson BA, Javors MA, Roache P, Seneviratne C, Bergeson SE, Ait-Daoud N, Dawes MA, Ma JZ. Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 Jan;32(1):209-216. |
| Miller PM, Spies C, Neumann T, Javors MA, Hoyumpa AM, Roache P, Webb AL, Kashi M, Sharkey FE, Anton RF, Egan BM, Basile J, Nguyen S, Fleming MF, Dillie KS. Alcohol Biomarker Screening in Medical and Surgical Settings Alcoholism: Clinical and Experimental Research 2006 Feb;30(2):185-193. |
Book Chapter |
| Roache, JD. Role of the human laboratory in the development of medications for alcohol and drug dependence. In: Johnson BA. Addiction Medicine: Science and Practice. New York: Springer Science & Business Media, LLC; 2010. p. 129-157. |
| Ginsburg BC, Gerak LR, McMahon LR, Roache JD. Neurosteroids in alcohol and substance use. In: Ritsner MS, Weizman A. Neuroactive Steroids in Brain Function, Behavioral and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment. New York, NY: Springer; 2008. p. 507-536. |
Abstract |
| Dawes MA, Mathias C, Richard DM, Roache, Ph.D. JD, Acheson A, Dougherty DM. Comparison of adolescents with alcohol use disorder, cannabis dependence, and controls recruited from the community; 2010 Jan. (Alcoholism: Clinical and Experimental Research; vol. 34, no. 6). |
| Javors, MA, Hoyumpa, A, Roache, J, Sharkey, F and King TS. Serum %CDT as a Biomarker for Liver Damage in Alcohol Abstainers Santa Barbara, CA; 2005 Jan. (28th Annual Scientific Meeting of the Research Society on Alcoholism). |
Federal |
|
| Funding Agency | U.S. Dept. Defense |
| Title | SSRI Treatment of PTSD and Alcohol Dependence Dual Diagnosis: A Test of the Serotonergic Hypothesis |
| Status | Active |
| Period | 9/2008 - 8/2013 |
| Role | Principal Investigator |
| Grant Detail | An experiment evaluating the serotonergic basis for differential treatment efficacy of SSRI''s in the treatment of Dual Diagnosis PTSD and Alcohol Dependence. |
| Funding Agency | NIDA |
| Title | TO #2 - Phase I Clinical Trial with Vigabatrin for Cocaine Dependence |
| Status | Complete |
| Period | 2/2007 - 10/2010 |
| Role | Principal Investigator |
| Grant Detail | Effort: 5% 6mons; 25% 2mons; 15% 12mons |